PPARδ modulation improves the bioenergetic defect in mitochondrial myopathy

Eric Bell1, Peter Dwyer1, Robert Shine1, Lyndsay Olson1, Erzsebet Polyak2, Yi Cheng2, Julian Ostrovksy2, Marni J. Falk2,3, Robert Taylor4, Dominique Stickens1, Effie Tozzo1
1 Mitobridge, Inc; 2 1030 Massachusetts Avenue, Cambridge MA 02138; 2 Division of Human Genetics, Department of Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; 3 Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104 USA; 4 Welcome Trust Centre for Mitochondrial Research, Newcastle University, Newcastle UK

Abstract
Mitochondrial disorders are a heterogeneous group of neuromuscular diseases. Despite extensive variation in the clinical phenotype, skeletal muscle weakness and fatigue are common hallmarks of mitochondrial myopathies leading to reduced mobility and endurance. Skeletal muscle, which accounts for much of the body’s energy consumption, generally oxidizes both fats and carbohydrates; however, in periods of prolonged activity fat becomes the primary source of energy. Fatty acid oxidation capacity may be impaired in primary mitochondrial respiratory chain diseases. Here, we evaluated whether fibroblasts from mitochondrial myopathy human subjects, with either a mutation in the MT-TL2 gene (MELAS), 5 kb common-deletion in Kearns-Sayre syndrome (KSS), or mutations in MT-ND4 and MT-ND6 genes (Leigh/LHON) effectively utilized fat as a substrate to support oxidative phosphorylation. Both MELAS and KSS lines exhibited markedly reduced mitochondrial respiration when fatty acids were used as the carbon source. Application of a novel modulator of the PPARδ nuclear receptor (MA-0211 aka MB-1, AF9367) to MELAS, KSS, and Leigh/LHON fibroblasts increased the expression of genes that regulate fatty acid oxidation. MA-0211 also increased mitochondrial respiratory capacity when fatty acids were used as the carbon source. Moreover, treating aged, diet-induced obese mice with MA-0211 significantly decreased their fatigue in an exercise endurance test. Together these results suggest that increasing fatty acid-mediated respiration may offer a valuable therapeutic approach to relieve fatigue and increase endurance in mitochondrial myopathy.

Introduction

Conclusions and Future Directions
Mitochondrial dysfunction has been increasingly recognized as an important contributor to an array of neuromuscular diseases. The current standard of care consists of a combination of nutritional supplements. A novel approach to treating mitochondrial myopathies (MM) is to identify therapeutics that can improve mitochondrial function in the muscle by increasing fuel utilization through fatty acid oxidation. We showed that MA-0211, a potent and selective modulator of PPARδ, can increase the expression of genes encoding proteins involved in OXPHOS in fibroblasts from MM patients. This leads to an increase in the utilization of fatty acids and an increase in mitochondrial respiration. Remarkably, an increase in mitochondrial respiration could be observed in fibroblasts from patients with a wide variety of mutations, indicating that PPAR5 modulation could potentially benefit most MM patients. In the in vitro effects of MA-0211 were also shown to translate in vivo by decreasing the fatigue index during running of DIO mice, indicating that the effect of increasing mitochondrial respiration is not just specific to fibroblasts but can also improve muscle function. In preclinical safety studies MA-0211 was shown to be safe and well tolerated. The next step will be to test this therapeutic in clinical trials.

Acknowledgments
We thank Carlos Morais for providing the MERRF cybrids and for his advice on experimental conditions.